GlaxoSmithKline PLC Logo

GlaxoSmithKline PLC

A biopharmaceutical company developing vaccines and specialty medicines to prevent and treat disease.

GSK | IL

Overview

Corporate Details

ISIN(s):
GB00BN7SWP63 (+1 more)
LEI:
5493000HZTVUYLO1D793
Country:
United Kingdom
Address:
79 NEW OXFORD STREET, WC1A 1DG LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GSK is a global biopharmaceutical company that unites science, technology, and talent to prevent and treat disease. The company focuses on the discovery, development, and manufacturing of innovative vaccines and specialty medicines. Its core research and development efforts are concentrated in four therapeutic areas: infectious diseases, HIV, oncology, and immunology/respiratory. Formed in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham, GSK has since sharpened its focus on biopharmaceuticals, notably after the 2022 demerger of its consumer healthcare business. The company is committed to improving global health by making its products accessible and affordable worldwide through strategic partnerships and access programs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 08:15
Transaction in Own Shares
Transaction in Own Shares
English 824.1 KB
2025-11-27 08:20
Transaction in Own Shares
Transaction in Own Shares
English 589.1 KB
2025-11-26 08:15
Transaction in Own Shares
Transaction in Own Shares
English 655.4 KB
2025-11-25 08:15
Transaction in Own Shares
Transaction in Own Shares
English 603.8 KB
2025-11-24 08:15
Transaction in Own Shares
Transaction in Own Shares
English 630.7 KB
2025-11-21 08:25
Legal Proceedings Report
Initiation of litigation against AnaptysBio Inc
English 14.8 KB
2025-11-21 08:15
Transaction in Own Shares
Transaction in Own Shares
English 1.2 MB
2025-11-20 08:15
Transaction in Own Shares
Transaction in Own Shares
English 816.4 KB
2025-11-19 09:35
Transaction in Own Shares
Transfer of Treasury Shares
English 8.2 KB
2025-11-19 08:20
Transaction in Own Shares
Transaction in Own Shares
English 783.9 KB
2025-11-18 16:40
Director's Dealing
Director/PDMR Shareholding
English 41.2 KB
2025-11-18 08:20
Transaction in Own Shares
Transaction in Own Shares
English 565.3 KB
2025-11-17 08:15
Transaction in Own Shares
Transaction in Own Shares
English 591.3 KB
2025-11-14 08:10
Transaction in Own Shares
Transaction in Own Shares
English 547.6 KB
2025-11-13 16:40
Director's Dealing
Director/PDMR Shareholding
English 88.3 KB

Automate Your Workflow. Get a real-time feed of all GlaxoSmithKline PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GlaxoSmithKline PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GlaxoSmithKline PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.